Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Status: Completed

Conditions: ALK-positive NSCLC

Treatments: Drug: brigatinib; Drug: alectinib; Drug: lorlatinib; Drug: crizotinib; Drug: ceritinib

Study type: Observational

Funder types: Industry

Identifiers

NCT04647110

B7461035

SEQUIA (Other Identifier)

Details and patient eligibility

About

This study aims to explore for the first time how the different ALK TKIs have been sequenced in real-world clinical practice and with which outcomes for Swedish lung cancer patients

Enrollment: 549 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Inclusion criteria for ALK-positive NSCLC patients will be based on prescription data i.e. defines eligible patients as adult patients with at least one filled prescription of ALK-inhibitors identified by the national prescription register. Only prescriptions filled at pharmacies can be captured in prescription registers, as they do not include data on hospital drugs. ALK-inhibitor treatments for patients with NSCLC are given primarily outside of the hospital setting minimizing the selection bias under the inclusion criteria.

Exclusion criteria

-not applicable

Trial design

549 participants in 1 patient group

Swedish Anaplastic lymphoma kinase (ALK) positive Non-small cell lung cancer (NSCLC) patients

Treatment:

Drug: brigatinib

Drug: crizotinib

Drug: lorlatinib

Drug: alectinib

Drug: ceritinib